ArticleDrug testing and analysis2026
Characterization of Novel Metabolites of the HIF Stabilizer JNJ-42041935 in Rats Using LC-HRMS for Doping Control Purposes: A Pilot Study.
Article in Drug testing and analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) stimulate erythropoiesis and enhance performance, and were banned by the World Anti-Doping Agency in the year 2011. JNJ-42041935, a potent and selective PHD inhibitor, was administered orally to Sprague-Dawley rats, and its metabolites were tentatively characterized using liquid chromatography-high-resolution mass spectrometry (LC-HRMS) in positive and negative ionization modes. Eleven metabolites were identified, with Phase I reactions including monohydroxylation, dechlorination, and decarboxylation, and Phase II reactions comprising methylation, glucuronidation, sulfation, glycine, and taurine conjugation. These results provide insights into JNJ-42041935 biotransformation and support the development of analytical methods for HIF-PHI detection in anti-doping control. Future studies will continue to identify and characterize the valuable metabolites of JNJ-42041935, with a view to providing a more comprehensive understanding of its in vivo metabolic profile and developing improved detection methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.